Research programme: anticancer therapies - ImmunoGen/Avalon
Alternative Names: Cancer antibodies - ImmunoGen/AvalonLatest Information Update: 15 Feb 2024
Price :
$50 *
At a glance
- Originator ImmunoGen
- Developer Avalon Pharmaceuticals; ImmunoGen
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 30 Dec 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 18 Mar 2003 No development reported - Preclinical for Cancer in USA (unspecified route)